Spero Therapeutics, Inc.
Spero Therapeutics, Inc. (SPRO): 11 pipeline candidates · 7 upcoming catalysts · ~22 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
21.8 months
D/E 0.12 · 0% dilution
Lead: Approved
11 candidates
7 upcoming, next in ~879d
0 buys · 8 sells (180d)
A transparent, data-derived signal for Spero Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$122.2M
Cash
$56.1M
Quarterly Burn
$7.8M
Runway
21.8 mo
Revenue
$258K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| acetaminophen | Approved |
| bupivacaine | Approved |
| dummy | Phase 3 |
| dummy infusion | Phase 3 |
| imipenem-cilastatin | Phase 3 |
| lidocaine | Approved |
| magnesium | Approved |
| spr206 | Phase 2 |
| spr720 | Phase 2 |
| tbp-pi-hbr | Phase 1 |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (7)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$22.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,599,760 | $8.4M |
| renaissance technologies llc | 1,189,235 | $2.8M |
| two sigma investments, lp | 885,631 | $2.1M |
| geode capital management, llc | 519,922 | $1.2M |
| blackrock, inc. | 433,202 | $1.0M |
| citadel advisors llc | 425,658 | $996K |
| susquehanna international group, llp | 381,615 | $893K |
| vanguard fiduciary trust co | 264,115 | $618K |
| state street corp | 214,751 | $503K |
| ionic capital management llc | 195,939 | $458K |
Showing top 10 of 46 institutional holders of Spero Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Spero Therapeutics, Inc.'s pipeline?
Spero Therapeutics, Inc. (SPRO) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Spero Therapeutics, Inc.'s lead drug candidate?
Spero Therapeutics, Inc.'s most advanced tracked candidate is acetaminophen (Approved) for 1 INDICATIONS AND USAGE Acetaminophen injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older the reduction of fever in adult and pediatric patients. Acetaminophen injection is indicated for the Management of mild to moderate pain in adult and pediatric patients 2 years and older ( 1 ) Management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older ( 1 ) Reduction of fever in adult and pediatric patients ( 1 ).
What is Spero Therapeutics, Inc.'s next catalyst?
Spero Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: OFIRMEV" — expected November 13, 2028.
What is Spero Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Spero Therapeutics, Inc. has approximately 21.8 months of cash runway.
What is Spero Therapeutics, Inc.'s market capitalization?
Spero Therapeutics, Inc.'s market capitalization is approximately $122.2M.
Get the full picture on Spero Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.